Aerovate Therapeutics enters at-the-market offering for $75M in common stock

In a regulatory 8-K filing, the company states: On April 5, 2023, Aerovate Therapeutics "entered into an ATM Equity Offering Sales Agreement with BofA Securities, Inc. with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its discretion, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 through BofA as its sales agent or to BofA as principal for its own account. The issuance and sale, if any, of the Shares by the Company under the Sales Agreement will be made pursuant to the Company’s effective registration statement on Form S-3. If the Company sells shares to BofA as principal, the Company will enter into a separate terms agreement with BofA setting forth the terms of such transaction, and the Company will describe this agreement in a separate pricing supplement."